Salute e Benessere
Mycenax and SPERA PHARMA Forge Strategic Alliance to Streamline ADC Drug Substance and Drug Product Manufacturing Services
Founded in 2017 as a spin-off from Takeda Pharmaceutical Company's CMC Research Division, SPERA PHARMA is recognized for its deep experience in complex drug development, including process chemistry, formulation, analytical development, and GMP-compliant aseptic manufacturing. Building on Japan's leading pharmaceutical heritage, SPERA PHARMA is considered one of the country's top CDMOs, trusted by global partners for its technical excellence and integrated CMC solutions.
Mycenax is a global biologics CDMO audited by international regulatory agencies including EMA, PMDA, and Health Canada. Its 2022 strategic partnership with KriSan Biotech further expanded its next-generation ADC technology platform.
Together, Mycenax and SPERA PHARMA offer an end-to-end development and manufacturing solution. This empowers global ADC developers with speed, flexibility, and technical excellence.
SPERA PHARMA, founded in July 2017 in Osaka, Japan , is a contract development and manufacturing organization (CDMO) specializing in Chemistry, Manufacturing and Controls (CMC). Its expertise spans process chemistry, formulation development, analytical sciences, and GMP-compliant manufacturing of investigational drugs. Backed by a team of highly experienced researchers with a strong track record, SPERA PHARMA provides flexible support across all phases of pharmaceutical development from early research to regulatory approval. As a one-stop provider of comprehensive CMC solutions, the company is committed to meeting the diverse needs of global clients. For further information, please visit spera-pharma.co.jp/en
Mycenax, a Taiwan -based CDMO, delivers integrated biologics solutions from process development to cGMP-compliant manufacturing. With two GMP-compliant manufacturing facilities and a strategic partnership with KriSan Biotech, Mycenax is committed to developing and manufacturing ADC therapeutics for the global market. For further information, please visit https://www.mycenax.com/
View original content:https://www.prnewswire.co.uk/news-releases/mycenax-and-spera-pharma-forge-strategic-alliance-to-streamline-adc-drug-substance-and-drug-product-manufacturing-services-302550054.html